OrthoPediatrics Corp. Common Stock (KIDS)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach OrthoPediatrics as a specialized pediatric orthopedics company making implants, instruments, and braces for children. The niche is understandable, but I cannot verify a durable moat from the figures alone: revenue grew from $148.7 million in fiscal 2023 to $204.7 million in fiscal 2024 and $236.3 million in fiscal 2025, yet profits have not followed. Fiscal 2025 produced a net loss of $39.6 million and diluted EPS of -$1.69; fiscal 2024 lost $37.8 million, and fiscal 2023 lost $21.0 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $70.5 million and net income was -$7.2 million, so growth has not yet become profitability. Free cash flow is -$1.8 million on a trailing basis, and the FairStock FCF yield is -0.3%. Financial health is mixed: debt-to-equity is 0.32, the FairStock Altman Z-score is 2.07, and the FairStock Piotroski F-score is 6/9. At the $24.02 close on 2026-10-26, the FairStock P/B is 1.83 and P/E is -14.30, the latter not meaningful with losses. FairStock calls it a TURNAROUND—loss in the latest year after earlier profits—and the numbers support that label. The business has revenue momentum and a specialized position, but no demonstrated earnings power or positive free cash flow. The stock is not statistically expensive on book value, but a Graham-style investor needs evidence that margins and cash generation are turning before calling it a bargain.

In plain English: The company makes implants, instruments, and braces for children with orthopedic conditions. Sales are growing and debt is modest, but it is still losing money and cash generation is slightly negative. At $24.02, the price looks neither clearly cheap nor clearly expensive against the reported numbers; it is a loss-making turnaround candidate.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer